What happens to babies exposed to phencyclidine (PCP) in utero?
Fifty-seven infants exposed to phencyclidine (PCP) in utero were followed for the first year of life. Thirty-six (65%) of the 55 for whom birth records were available manifested symptoms of neonatal narcotic withdrawal syndrome, including 16 (52%) of those whose mothers denied opiate abuse during pregnancy. Temperament problems were noted in 47% of the babies and sleep problems in 14%. The majority of infants grew normally, but a larger than expected number started out small and remained small. Testing using the Bayley Scales of Infant Development at age one year revealed a mental development index (mean +/- SD) of 94 +/- 10 and a psychomotor development index of 98 +/- 10. Attachment behavior was abnormal in 17%. Most infants were cared for by their natural mother. Further studies are needed to determine later effects of in utero PCP exposure, as well as effects on the infants being raised by women who have used PCP. Phencyclidine toxicity needs to be considered when evaluating babies with signs of neonatal narcotic withdrawal syndrome.
Wachsman
L
L
Department of Pediatrics, Los Angeles County-University of Southern California Medical Center 90033.
Schuetz
S
S
Chan
L S
LS
Wingert
W A
WA
D001724:Birth Weight; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015141:Los Angeles; D009357:Neonatal Abstinence Syndrome / Q000453:epidemiology; D010622:Phencyclidine / Q000009:adverse effects*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D012893:Sleep Wake Disorders / Q000209:etiology; D013694:Temperament
D010622:Phencyclidine